Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 325 to 331 of 331 entries
Sorted by: Best Match Show Resources per page
Management of HIV/hepatitis C virus-coinfected patient non-responders to hepatitis C virus antiviral therapy and relapsers.

Current opinion in HIV and AIDS

Tural C, Planas R, Sirera G, Clotet B.
PMID: 19372933
Curr Opin HIV AIDS. 2007 Nov;2(6):496-502. doi: 10.1097/COH.0b013e3282f0dce1.

PURPOSE OF REVIEW: To examine recent developments in the management of HIV/hepatitis C virus-coinfected patients who relapsed or who responded poorly to initial therapy, with particular emphasis on peginterferon plus ribavirin.RECENT FINDINGS: End-stage liver disease is the first cause...

Cite
Tural C, Planas R, Sirera G, et al. Management of HIV/hepatitis C virus-coinfected patient non-responders to hepatitis C virus antiviral therapy and relapsers. Curr Opin HIV AIDS. 2007;2(6):496-502doi: 10.1097/COH.0b013e3282f0dce1.
Tural, C., Planas, R., Sirera, G., & Clotet, B. (2007). Management of HIV/hepatitis C virus-coinfected patient non-responders to hepatitis C virus antiviral therapy and relapsers. Current opinion in HIV and AIDS, 2(6), 496-502. https://doi.org/10.1097/COH.0b013e3282f0dce1
Tural, Cristina, et al. "Management of HIV/hepatitis C virus-coinfected patient non-responders to hepatitis C virus antiviral therapy and relapsers." Current opinion in HIV and AIDS vol. 2,6 (2007): 496-502. doi: https://doi.org/10.1097/COH.0b013e3282f0dce1
Tural C, Planas R, Sirera G, Clotet B. Management of HIV/hepatitis C virus-coinfected patient non-responders to hepatitis C virus antiviral therapy and relapsers. Curr Opin HIV AIDS. 2007 Nov;2(6):496-502. doi: 10.1097/COH.0b013e3282f0dce1. PMID: 19372933.
Copy Download .nbib Format: NLM
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.

Life science alliance

Varona JF, Landete P, Lopez-Martin JA, Estrada V, Paredes R, Guisado-Vasco P, Fernandez de Orueta L, Torralba M, Fortun J, Vates R, Barberan J, Clotet B, Ancochea J, Carnevali D, Cabello N, Porras L, Gijon P, Monereo A, Abad D, Zuñiga S, Sola I, Rodon J, Vergara-Alert J, Izquierdo-Useros N, Fudio S, Pontes MJ, de Rivas B, Giron de Velasco P, Nieto A, Gomez J, Aviles P, Lubomirov R, Belgrano A, Sopesen B, White KM, Rosales R, Yildiz S, Reuschl AK, Thorne LG, Jolly C, Towers GJ, Zuliani-Alvarez L, Bouhaddou M, Obernier K, McGovern BL, Rodriguez ML, Enjuanes L, Fernandez-Sousa JM, Krogan NJ, Jimeno JM, Garcia-Sastre A, Keränen L.
PMID: 35012962
Life Sci Alliance. 2022 Jan 10;5(4). doi: 10.26508/lsa.202101200. Print 2022 Apr.

Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar concentrations by targeting the host protein eukaryotic translation elongation factor 1A. Here, we show that plitidepsin distributes preferentially to lung over plasma, with similar potency against across several SARS-CoV-2 variants...

Cite
Varona JF, Landete P, Lopez-Martin JA, et al. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19. Life Sci Alliance. 2022;5(4)doi: 10.26508/lsa.202101200.
Varona, J. F., Landete, P., Lopez-Martin, J. A., Estrada, V., Paredes, R., Guisado-Vasco, P., Fernandez de Orueta, L., Torralba, M., Fortun, J., Vates, R., Barberan, J., Clotet, B., Ancochea, J., Carnevali, D., Cabello, N., Porras, L., Gijon, P., Monereo, A., Abad, D., Zuñiga, S., Sola, I., Rodon, J., Vergara-Alert, J., Izquierdo-Useros, N., Fudio, S., Pontes, M. J., de Rivas, B., Giron de Velasco, P., Nieto, A., Gomez, J., Aviles, P., Lubomirov, R., Belgrano, A., Sopesen, B., White, K. M., Rosales, R., Yildiz, S., Reuschl, A. K., Thorne, L. G., Jolly, C., Towers, G. J., Zuliani-Alvarez, L., Bouhaddou, M., Obernier, K., McGovern, B. L., Rodriguez, M. L., Enjuanes, L., Fernandez-Sousa, J. M., Krogan, N. J., Jimeno, J. M., Garcia-Sastre, A., & Keränen, L. (2022). Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19. Life science alliance, 5(4), . https://doi.org/10.26508/lsa.202101200
Varona, Jose F, et al. "Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19." Life science alliance vol. 5,4 (2022). doi: https://doi.org/10.26508/lsa.202101200
Varona JF, Landete P, Lopez-Martin JA, Estrada V, Paredes R, Guisado-Vasco P, Fernandez de Orueta L, Torralba M, Fortun J, Vates R, Barberan J, Clotet B, Ancochea J, Carnevali D, Cabello N, Porras L, Gijon P, Monereo A, Abad D, Zuñiga S, Sola I, Rodon J, Vergara-Alert J, Izquierdo-Useros N, Fudio S, Pontes MJ, de Rivas B, Giron de Velasco P, Nieto A, Gomez J, Aviles P, Lubomirov R, Belgrano A, Sopesen B, White KM, Rosales R, Yildiz S, Reuschl AK, Thorne LG, Jolly C, Towers GJ, Zuliani-Alvarez L, Bouhaddou M, Obernier K, McGovern BL, Rodriguez ML, Enjuanes L, Fernandez-Sousa JM, Krogan NJ, Jimeno JM, Garcia-Sastre A, Keränen L. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19. Life Sci Alliance. 2022 Jan 10;5(4). doi: 10.26508/lsa.202101200. Print 2022 Apr. PMID: 35012962.
Copy Download .nbib Format: NLM
Baseline Susceptibility of .

Insects

Kulye M, Mehlhorn S, Boaventura D, Godley N, Venkatesh SK, Rudrappa T, Charan T, Rathi D, Nauen R.
PMID: 34442324
Insects. 2021 Aug 23;12(8). doi: 10.3390/insects12080758.

Fall armyworm (FAW),

Cite
Kulye M, Mehlhorn S, Boaventura D, et al. Baseline Susceptibility of . Insects. 2021;12(8)doi: 10.3390/insects12080758.
Kulye, M., Mehlhorn, S., Boaventura, D., Godley, N., Venkatesh, S. K., Rudrappa, T., Charan, T., Rathi, D., & Nauen, R. (2021). Baseline Susceptibility of . Insects, 12(8), . https://doi.org/10.3390/insects12080758
Kulye, Mahesh, et al. "Baseline Susceptibility of ." Insects vol. 12,8 (2021). doi: https://doi.org/10.3390/insects12080758
Kulye M, Mehlhorn S, Boaventura D, Godley N, Venkatesh SK, Rudrappa T, Charan T, Rathi D, Nauen R. Baseline Susceptibility of . Insects. 2021 Aug 23;12(8). doi: 10.3390/insects12080758. PMID: 34442324; PMCID: PMC8397139.
Copy Download .nbib Format: NLM
Cardiogenic shock: incidence, survival and mechanical circulatory support usage 2007-2017-insights from a national registry.

Clinical research in cardiology : official journal of the German Cardiac Society

Lang CN, Kaier K, Zotzmann V, Stachon P, Pottgiesser T, von Zur Muehlen C, Zehender M, Duerschmied D, Schmid B, Bode C, Wengenmayer T, Staudacher DL.
PMID: 33258007
Clin Res Cardiol. 2021 Sep;110(9):1421-1430. doi: 10.1007/s00392-020-01781-z. Epub 2020 Nov 30.

BACKGROUND: A central element in the management of cardiogenic shock (CS) comprises mechanical circulatory support (MCS) systems to maintain cardiac output (CO). This study aims to quantify incidence, outcome and influence of MCS in CS over the last decade.METHODS:...

Cite
Lang CN, Kaier K, Zotzmann V, et al. Cardiogenic shock: incidence, survival and mechanical circulatory support usage 2007-2017-insights from a national registry. Clin Res Cardiol. 2020;110(9):1421-1430doi: 10.1007/s00392-020-01781-z.
Lang, C. N., Kaier, K., Zotzmann, V., Stachon, P., Pottgiesser, T., von Zur Muehlen, C., Zehender, M., Duerschmied, D., Schmid, B., Bode, C., Wengenmayer, T., & Staudacher, D. L. (2021). Cardiogenic shock: incidence, survival and mechanical circulatory support usage 2007-2017-insights from a national registry. Clinical research in cardiology : official journal of the German Cardiac Society, 110(9), 1421-1430. https://doi.org/10.1007/s00392-020-01781-z
Lang, Corinna N, et al. "Cardiogenic shock: incidence, survival and mechanical circulatory support usage 2007-2017-insights from a national registry." Clinical research in cardiology : official journal of the German Cardiac Society vol. 110,9 (2021): 1421-1430. doi: https://doi.org/10.1007/s00392-020-01781-z
Lang CN, Kaier K, Zotzmann V, Stachon P, Pottgiesser T, von Zur Muehlen C, Zehender M, Duerschmied D, Schmid B, Bode C, Wengenmayer T, Staudacher DL. Cardiogenic shock: incidence, survival and mechanical circulatory support usage 2007-2017-insights from a national registry. Clin Res Cardiol. 2021 Sep;110(9):1421-1430. doi: 10.1007/s00392-020-01781-z. Epub 2020 Nov 30. PMID: 33258007; PMCID: PMC8405485.
Copy Download .nbib Format: NLM
Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.

Frontiers in pharmacology

Rodon J, Muñoz-Basagoiti J, Perez-Zsolt D, Noguera-Julian M, Paredes R, Mateu L, Quiñones C, Perez C, Erkizia I, Blanco I, Valencia A, Guallar V, Carrillo J, Blanco J, Segalés J, Clotet B, Vergara-Alert J, Izquierdo-Useros N.
PMID: 33841165
Front Pharmacol. 2021 Mar 25;12:646676. doi: 10.3389/fphar.2021.646676. eCollection 2021.

There is an urgent need to identify therapeutics for the treatment of Coronavirus disease 2019 (COVID-19). Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing...

Cite
Rodon J, Muñoz-Basagoiti J, Perez-Zsolt D, et al. Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen. Front Pharmacol. 2021;12:646676doi: 10.3389/fphar.2021.646676.
Rodon, J., Muñoz-Basagoiti, J., Perez-Zsolt, D., Noguera-Julian, M., Paredes, R., Mateu, L., Quiñones, C., Perez, C., Erkizia, I., Blanco, I., Valencia, A., Guallar, V., Carrillo, J., Blanco, J., Segalés, J., Clotet, B., Vergara-Alert, J., & Izquierdo-Useros, N. (2021). Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen. Frontiers in pharmacology, 12646676. https://doi.org/10.3389/fphar.2021.646676
Rodon, Jordi, et al. "Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen." Frontiers in pharmacology vol. 12 (2021): 646676. doi: https://doi.org/10.3389/fphar.2021.646676
Rodon J, Muñoz-Basagoiti J, Perez-Zsolt D, Noguera-Julian M, Paredes R, Mateu L, Quiñones C, Perez C, Erkizia I, Blanco I, Valencia A, Guallar V, Carrillo J, Blanco J, Segalés J, Clotet B, Vergara-Alert J, Izquierdo-Useros N. Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen. Front Pharmacol. 2021 Mar 25;12:646676. doi: 10.3389/fphar.2021.646676. eCollection 2021. PMID: 33841165; PMCID: PMC8033486.
Copy Download .nbib Format: NLM
Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication.

The New England journal of medicine

John LN, Beiras CG, Houinei W, Medappa M, Sabok M, Kolmau R, Jonathan E, Maika E, Wangi JK, Pospíšilová P, Šmajs D, Ouchi D, Galván-Femenía I, Beale MA, Giacani L, Clotet B, Mooring EQ, Marks M, Vall-Mayans M, Mitjà O.
PMID: 34986286
N Engl J Med. 2022 Jan 06;386(1):47-56. doi: 10.1056/NEJMoa2109449.

METHODS: In an open-label, cluster-randomized, community-based trial conducted in a yaws-endemic area of Papua New Guinea, we randomly assigned 38 wards (i.e., clusters) to receive one round of mass administration of azithromycin followed by two rounds of target treatment...

Cite
John LN, Beiras CG, Houinei W, et al. Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication. N Engl J Med. 2022;386(1):47-56doi: 10.1056/NEJMoa2109449.
John, L. N., Beiras, C. G., Houinei, W., Medappa, M., Sabok, M., Kolmau, R., Jonathan, E., Maika, E., Wangi, J. K., Pospíšilová, P., Šmajs, D., Ouchi, D., Galván-Femenía, I., Beale, M. A., Giacani, L., Clotet, B., Mooring, E. Q., Marks, M., Vall-Mayans, M., & Mitjà, O. (2022). Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication. The New England journal of medicine, 386(1), 47-56. https://doi.org/10.1056/NEJMoa2109449
John, Lucy N, et al. "Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication." The New England journal of medicine vol. 386,1 (2022): 47-56. doi: https://doi.org/10.1056/NEJMoa2109449
John LN, Beiras CG, Houinei W, Medappa M, Sabok M, Kolmau R, Jonathan E, Maika E, Wangi JK, Pospíšilová P, Šmajs D, Ouchi D, Galván-Femenía I, Beale MA, Giacani L, Clotet B, Mooring EQ, Marks M, Vall-Mayans M, Mitjà O. Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication. N Engl J Med. 2022 Jan 06;386(1):47-56. doi: 10.1056/NEJMoa2109449. PMID: 34986286; PMCID: PMC7612200.
Copy Download .nbib Format: NLM
Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication.

The New England journal of medicine

John LN, Beiras CG, Houinei W, Medappa M, Sabok M, Kolmau R, Jonathan E, Maika E, Wangi JK, Pospíšilová P, Šmajs D, Ouchi D, Galván-Femenía I, Beale MA, Giacani L, Clotet B, Mooring EQ, Marks M, Vall-Mayans M, Mitjà O.
PMID: 34986286
N Engl J Med. 2022 Jan 06;386(1):47-56. doi: 10.1056/NEJMoa2109449.

METHODS: In an open-label, cluster-randomized, community-based trial conducted in a yaws-endemic area of Papua New Guinea, we randomly assigned 38 wards (i.e., clusters) to receive one round of mass administration of azithromycin followed by two rounds of target treatment...

Cite
John LN, Beiras CG, Houinei W, et al. Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication. N Engl J Med. 2022;386(1):47-56doi: 10.1056/NEJMoa2109449.
John, L. N., Beiras, C. G., Houinei, W., Medappa, M., Sabok, M., Kolmau, R., Jonathan, E., Maika, E., Wangi, J. K., Pospíšilová, P., Šmajs, D., Ouchi, D., Galván-Femenía, I., Beale, M. A., Giacani, L., Clotet, B., Mooring, E. Q., Marks, M., Vall-Mayans, M., & Mitjà, O. (2022). Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication. The New England journal of medicine, 386(1), 47-56. https://doi.org/10.1056/NEJMoa2109449
John, Lucy N, et al. "Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication." The New England journal of medicine vol. 386,1 (2022): 47-56. doi: https://doi.org/10.1056/NEJMoa2109449
John LN, Beiras CG, Houinei W, Medappa M, Sabok M, Kolmau R, Jonathan E, Maika E, Wangi JK, Pospíšilová P, Šmajs D, Ouchi D, Galván-Femenía I, Beale MA, Giacani L, Clotet B, Mooring EQ, Marks M, Vall-Mayans M, Mitjà O. Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication. N Engl J Med. 2022 Jan 06;386(1):47-56. doi: 10.1056/NEJMoa2109449. PMID: 34986286; PMCID: PMC7612200.
Copy Download .nbib Format: NLM
Showing 325 to 331 of 331 entries